FDA Approves SPIRONOLACTONE — Rising Pharma Holdings, Inc.

Rising Pharma Holdings, Inc. received FDA approval Monday to market its generic version of the antihypertensive and diuretic Spirionolactone (ANDA219494), potentially broadening access to cost-effective cardiovascular therapies and intensifying competition in the established generic market. The approval is anticipated to enable the company to capture revenue from an upcoming patent cliff, placing immediate pressure on pricing and market share for competing branded formulations.